It’s Time to Put Guardrails on GLP-1 Compounding

Why It Matters

Unchecked compounding threatens patient safety and undermines confidence in prescription drug markets, prompting urgent regulatory and legislative action.

Key Takeaways

• FDA logged 1,150 adverse events from compounded GLP‑1 drugs.
• Compounded GLP‑1 sales surged during 2022‑2025 shortage.
• Hims & Hers received warning letters after selling unapproved GLP‑1 pill.
• SAFE Drugs Act aims to tighten API sourcing and FDA oversight.
• API often sourced from China, quality varies widely.

Pulse Analysis

The surge in GLP‑1 therapies, driven by rising obesity rates and demand for weight‑loss solutions, exposed a critical supply gap that compounding pharmacies moved to fill. While legitimate compounding can address individualized dosing needs, the pandemic‑era shortage of semaglutide and tirzepatide turned the practice into a profit‑driven gold rush. Companies began offering bulk‑produced, “personalized” formulations, often adding vitamins or micro‑doses without any clinical validation, creating a parallel market that operates outside traditional drug‑approval pathways.

Regulators have struggled to keep pace with this expansion. The FDA’s exemption for “one‑drug‑for‑one‑person” compounding allowed pharmacies to bypass rigorous testing, adverse‑event reporting, and quality‑control mandates. Consequently, the agency received over a thousand adverse‑event reports, many involving severe reactions or hospitalizations. Enforcement actions, including warning letters to more than 55 online sellers and a swift shutdown of Hims & Hers’ unapproved GLP‑1 pill, underscore the urgency of closing loopholes that enable mass‑scale compounding without oversight.

Legislative momentum now centers on the Safeguarding Americans from Fraudulent and Experimental (SAFE) Drugs Act, which would require active pharmaceutical ingredients to originate from inspected, registered facilities and empower the FDA to restrict non‑approved API use. If enacted, the law could restore confidence in the compounding ecosystem, protect consumers from substandard products, and re‑establish clear boundaries between personalized pharmacy services and large‑scale drug manufacturing. Industry players will need to adapt quickly, ensuring supply chains meet stricter standards while preserving legitimate compounding services for patients with genuine dosing needs.